People: OncoGenex Pharmaceuticals Inc (OGXI.PH)
OGXI.PH on Philadelphia Stock Exchange
9.95USD
17 Jun 2013
9.95USD
17 Jun 2013
Price Change (% chg)
$0.00 (+0.00%)
$0.00 (+0.00%)
Prev Close
$9.95
$9.95
Open
$9.95
$9.95
Day's High
$9.95
$9.95
Day's Low
$9.95
$9.95
Volume
100
100
Avg. Vol
--
--
52-wk High
--
--
52-wk Low
--
--
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Jack Goldstein |
65 | 2010 | Independent Chairman of the Board |
Scott Cormack |
2013 | President, Chief Executive Officer, Principal Financial Officer, Secretary, Director | |
Cindy Jacobs |
54 | 2008 | Executive Vice President, Chief Medical Officer |
Susan Wyrick |
40 | 2013 | Principal Accounting Officer |
Neil Clendeninn |
62 | 2008 | Independent Director |
Martin Mattingly |
54 | 2010 | Independent Director |
H. Stewart Parker |
56 | 2010 | Independent Director |
David Smith |
52 | 2010 | Independent Director |
Susan Specht |
Director, Investor Relations |
Biographies
| Name | Description |
|---|---|
Jack Goldstein |
Dr. Jack Goldstein, Ph.D., is Independent Chairman of the Board of Directors of OncoGenex Pharmaceuticals Inc. Dr. Goldstein was President and Chief Operating Officer of Chiron Corporation, a biotechnology company, from November 2004 until its acquisition by Novartis AG in April 2006, prior to which he served as Vice President and President, Chiron Blood Testing Division beginning in 2002. From 2000 to 2002, Dr. Goldstein was General Partner at Windamere Venture Partners, L.L.C., a venture capital fund. From 1997 to 2001, he served as President and Chief Executive Officer of Applied Imaging Corporation, a supplier of instrument systems for prenatal and cancer genetics, where he also served as Chairman of the Board of Directors from 1999 to 2002. Dr. Goldstein currently serves on the Board of Directors of Accuray Incorporated and has served as a director of Orasure Technologies Inc. from May 2006 to May 2011, Illumina, Inc. from June 2006 to May 2010, and Immucor, Inc. from December 2007 to February 2009. Dr. Goldstein holds a B.A. degree in biology from Rider University, and a M.S. degree in immunology and a Ph.D. degree in microbiology from St. John’s University. |
Scott Cormack |
Mr. Scott Daniel Cormack is President, Chief Executive Officer, Principal Financial Officer, Secretary, Director of OncoGenex Pharmaceuticals Inc. He was a co-founder of OncoGenex Technologies Inc., which is wholly owned subsidiary, and has been its President since May 2000, its Chief Executive Officer since February 2002 and a member of its Board of Directors since May 2000. Mr. Cormack served as interim President, Chief Executive Officer and Chairman of the Board of Directors of Salpep Biotechnology Inc., an asthma and inflammation biotechnology company, from 2000 to 2001. From 1998 to 2001, Mr. Cormack served as Vice President of Milestone Medica Corporation, a seed venture capital firm investing in life sciences opportunities. Mr. Cormack holds a B.S. degree from the University of Alberta. |
Cindy Jacobs |
Dr. Cindy Jacobs, Ph.D., M.D., is Executive Vice President and Chief Medical Officer of OncoGenex Pharmaceuticals, Inc. She had been Executive Vice President and Chief Medical Officer of OncoGenex Technologies Inc. from September 2005 to August 2008. From 1999 to July 2005, Dr. Jacobs served as Chief Medical Officer and Senior Vice President, Clinical Development of Corixa Corporation. Prior to 1999, Dr. Jacobs held Vice President, Clinical Research positions at two other biopharmaceutical companies. Dr. Jacobs received her Ph.D. degree in Veterinary Pathology/Microbiology from Washington State University and an M.D. degree from the University of Washington Medical School. |
Susan Wyrick |
Ms. Susan Wyrick is appointed as the Principal Accounting Officer of OncoGenex Pharmaceuticals, Inc. She has also served as the Company’s Senior Director of Finance since June 2012. Prior to joining the Company, Ms. Wyrick served as the Director, Site Controller at Emergent BioSolutions Inc., a biopharmaceutical company, from November 2010 to June 2012, where her duties included managing the accounting department and preparing operating plans and forecasts. From March 2006 to October 2010, Ms. Wyrick served as the Controller at Trubion Pharmaceuticals, Inc., a biopharmaceutical company, which was acquired by Emergent BioSolutions Inc. in October 2010. As Controller, Ms. Wyrick’s responsibilities included managing the accounting department and the annual financial audit. Prior to March 2006, Ms. Wyrick served in senior financial positions at publicly-held biotechnology companies. Ms. Wyrick received a B.A. in Business Administration from the University of Washington and has passed the CPA exam. |
Neil Clendeninn |
Dr. Neil James Clendeninn, M.D., Ph.D., is Independent Director of OncoGenex Pharmaceuticals Inc. Additionally, he has served as a member of OncoGenex Technologies Inc.’s Board of Directors since September 2004. Dr. Clendeninn served as Corporate Vice President, Head of Clinical Affairs of Agouron Pharmaceuticals, Inc., a biopharmaceutical company and a subsidiary of Pfizer Inc., a pharmaceutical company, from 1993 until his retirement in 2001. Dr. Clendeninn holds a B.A. degree in biology/chemistry from Wesleyan University, and a Ph.D. degree in microbiology/pharmacology and an M.D. degree from New York University. |
Martin Mattingly |
Dr. Martin A. Mattingly, Pharm.D, is Independent Director of OncoGenex Pharmaceuticals, Inc. Dr. Mattingly served as the Chief Executive Officer of Trimeris, Inc., a biopharmaceutical company, from November 2007 until its merger with Synageva in November 2011. He also served on the Board of Directors of Trimeris, Inc. from November 2007 until November 2011. From 2005 to 2007, Dr. Mattingly was employed at Ambrx, Inc., a biopharmaceutical company, where he served as President and Chief Executive Officer. From 2003 to 2005, Dr. Mattingly served as Executive Vice President and Chief Operating Officer of CancerVax Corporation, a biotechnology company. From 1996 to 2003, he provided senior leadership in various management positions at Agouron Pharmaceuticals, Inc. and Pfizer, Inc., including serving as General Manager of the Agouron HIV division, Vice President, Product Development Group at Pfizer and Vice President, Global Marketing Planning at Pfizer. Dr. Mattingly holds a Pharm.D. degree from the University of Kentucky. |
H. Stewart Parker |
Ms. H. Stewart Parker is Independent Director of OncoGenex Pharmaceuticals Inc. Ms. Parker has served as the Chief Executive Officer of the Infectious Disease Research Institute, or IDRI, a nonprofit research organization focused on the development of products for the diagnosis, prevention, and treatment of neglected diseases since March 2011. Prior to IDRI, Ms. Parker managed the formation of Targeted Genetics Corporation, a biotechnology company, as a wholly owned subsidiary of Immunex Corporation, a biotechnology company, and served as its President and Chief Executive Officer and as a director from its spinout from Immunex Corporation in 1992 to November 2008. She served in various capacities at Immunex Corporation from August 1981 through December 1991, most recently as Vice President, Corporate Development. She serves on the Board of Directors and the executive committee of BIO, the primary trade organization for the biotechnology industry. Ms. Parker has also served as a director of Targeted Genetics Corporation from 1992 to November 2008 and Neose Technologies, Inc. from May 2005 to January 2009. Ms. Parker received her B.A. and M.B.A. degrees from the University of Washington. |
David Smith |
Mr. David V. Smith is Independent Director of OncoGenex Pharmaceuticals, Inc. From December 2006 to July 2011, Mr. Smith was the Executive Vice President and Chief Financial Officer of Thoratec Corporation, a medical device company. Mr. Smith served as the Vice President and Chief Financial Officer of Chiron Corporation from April 2003 to April 2006, as its Vice President, Finance from February 2002 to April 2003 and as its Vice President and Principal Accounting Officer from February 1999 to February 2002. Mr. Smith earned a B.A degree in economics and history from Willamette University and a M.B.A degree in finance from Golden Gate University. In the past five years, he served as a director and chair of the audit committee of Perlegen Sciences, Inc. from May 2006 to November 2009. |
Susan Specht |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Jack Goldstein |
-- |
Scott Cormack |
683,339 |
Cindy Jacobs |
479,750 |
Susan Wyrick |
-- |
Neil Clendeninn |
-- |
Martin Mattingly |
-- |
H. Stewart Parker |
-- |
David Smith |
-- |
Susan Specht |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Jack Goldstein |
0 | 0 |
Scott Cormack |
23,660 | 269,258 |
Cindy Jacobs |
21,210 | 247,406 |
Susan Wyrick |
0 | 0 |
Neil Clendeninn |
0 | 0 |
Martin Mattingly |
0 | 0 |
H. Stewart Parker |
0 | 0 |
David Smith |
0 | 0 |
Susan Specht |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
CLENDENINN NEIL JAMES |
2,000 | $0.00 |
PARKER H STEWART |
2,000 | $0.00 |
MATTINGLY MARTIN A |
2,000 | $0.00 |
SMITH DAVID V |
2,000 | $0.00 |
GOLDSTEIN JACK |
2,000 | $0.00 |
CORMACK SCOTT DANIEL |
2,134 | $0.00 |
JACOBS CINDY A |
534 | $0.00 |
JACOBS CINDY A |
1,875 | $0.00 |
CORMACK SCOTT DANIEL |
4,688 | $0.00 |
CLENDENINN NEIL JAMES |
513 | $4.11 |
GOLDSTEIN JACK |
1,000 | $14.38 |
CORMACK SCOTT DANIEL |
7,000 | $4.11 |
CLENDENINN NEIL JAMES |
3,702 | $4.11 |
CORMACK SCOTT DANIEL |
34,167 | $4.11 |
MATTINGLY MARTIN A |
1,000 | $12.46 |
JACOBS CINDY A |
11,210 | $4.11 |
PARKER H STEWART |
3,000 | $10.09 |
CORMACK SCOTT DANIEL |
5,000 | $4.11 |
JACOBS CINDY A |
10,000 | $4.11 |
CORMACK SCOTT DANIEL |
5,000 | $0.00 |
CORMACK SCOTT DANIEL |
5,000 | $0.00 |
CLENDENINN NEIL JAMES |
3,347 | $3.89 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
